Tuesday, 17 November 2026Peptide medicines at the counter: price, coverage, supply, rules.

Reading as
What is this?
RulesUS

Peptide policy comment period closes as pharmacists are told to wait for the final HHS rules

The public comment window on the HHS draft that lets 503A pharmacies compound six unapproved peptides closed on November 13. Pharmacy experts advise waiting for the final text, and the AMA wants the policy rescinded.

Editorial illustration for the story: Peptide policy comment period closes as pharmacists are told to wait for the final HHS rules
Illustration: Peptide Town. Cut-paper collage, not data.

Who feels it

  • Pharmacies Rethink

    Experts advise waiting for the final text before investing; state boards can still be stricter than HHS.

  • Patients Adjust

    No change yet: the six peptides stay unapproved and need a prescription, and the pharmacy route may change before it is final.

  • Prescribers Adjust

    The AMA now opposes the policy, and prescribers still carry the choice to prescribe drugs with thin human data.

  • Sellers Adjust

    The AMA plans to push state and federal enforcement against telehealth platforms and online dispensaries selling these peptides.

  • Payers Passes by

    —

The peptide policy comment period at HHS closed on November 13, and pharmacists are being told not to build a business on the draft yet. The interim policy would let state licensed 503A pharmacies compound six unapproved peptides without federal enforcement, but its final wording is still open, and the American Medical Association now wants it withdrawn.

What the HHS draft lets pharmacies do

The draft covers six peptides that have never been approved as drugs: BPC-157, TB-500, KPV, Semax, MOTS-c and epitalon. HHS said in late October that it would not take certain enforcement steps against physicians and licensed 503A pharmacies that prepare them for named patients, as long as they meet a list of conditions. Each product may hold only one active ingredient, and only certain forms and routes are covered for each peptide. A prescription is still needed. Larger 503B outsourcing facilities, which can supply clinics without a named patient, are left out. The policy does not approve any of the six, and it does not change their legal status under federal compounding law, which would need a formal FDA rule.

The conditions fall mostly on the pharmacy. According to a review of the notice by the law firm Polsinelli, bulk ingredients must come from FDA registered makers that follow current good manufacturing practice and supply a certificate of analysis naming the plant. Identity, purity, potency and impurities must be tested. Oral products need records showing the peptide is actually absorbed. Labels must say the product is compounded and not for resale, and serious side effects and quality problems must be reported to the FDA through MedWatch and to state regulators. Our earlier report on small pharmacies and the six peptides set out how the plan reached this point.

Why the peptide policy comment period matters

HHS described the notice as a draft and gave the public an unusually short window to respond, which ran through November 13. Comments can change the conditions, the list of peptides or the forms allowed before the FDA writes a final rule. Matt Martin, vice president of clinical services at the compounding supplier PCCA, made that point to Drug Topics. "It's not guaranteed," he said of the current text, adding that a policy open for comment could still see changes. His advice to pharmacy leaders was to watch the process before they commit staff, suppliers and money to a new peptide line. "What you think is the requirement today may not be the requirement when this policy changes," Martin said.

"What you think is the requirement today may not be the requirement when this policy changes," Martin said.

The closing of the peptide policy comment period does not start any clock that the public can see. HHS has not said when it will respond to comments, publish a revised version or ask the FDA to begin formal rulemaking on each peptide. That leaves pharmacies, prescribers and patients in a holding pattern. A pharmacy that has already bought tested ingredients may have to change labels, records or routes if the final text moves. Patients who expected a quick switch from gray market vials to a pharmacy product may also wait longer, because many pharmacies are likely to hold back until the rules settle. The table below sets out the dates that are known so far.

DateStepStatus
Late October 2026HHS releases the interim enforcement policy for six peptidesDraft, in force as an enforcement stance
November 9, 2026AMA delegates vote to urge HHS and the FDA to rescind itAdopted AMA policy
November 13, 2026Public comment window closesClosed
No date setRevised policy or FDA rulemaking on each peptideNot announced

Doctors and pharmacists push back on the evidence

The strongest objection now comes from the AMA. At its interim meeting in Orlando, the AMA House of Delegates adopted policy urging HHS, the FDA and other federal agencies to rescind administrative policies that ease compounding of unapproved synthetic peptides, according to an AMA press release dated November 9. The group also said it would work with agencies and state boards on enforcement against compounding pharmacies, telehealth platforms and online dispensaries that sell such products. "By allowing pharmacies to compound unapproved synthetic peptide substances without sufficient evidence of their safety and efficacy, patients are at increased risk of serious harm," said AMA board member Ilse R. Levin.

Pharmacists have raised similar doubts. The American Pharmacists Association filed comments asking the FDA to let patient safety and rigorous science guide its review, Drug Topics reported. Brigid Groves, the association's vice president of professional affairs, said the evidence is too thin for clinicians to counsel patients with confidence on long term safety, drug interactions and outcomes. FDA reviewers had earlier concluded that none of the nominated peptides met the legal criteria for the official list of bulk substances, citing few human trials and doubts about how the products are characterized. That split between HHS leadership and its own scientists is the reason many pharmacy groups expect further changes to the final text.

State boards still decide access at the counter

Even a final federal policy would not settle who can fill a peptide prescription. The HHS notice binds only federal enforcement, and state boards of pharmacy may take a stricter line, so a pharmacy licensed in several states has to check each one before it dispenses. Boards have already acted on peptides outside the federal debate, as when the Ohio Board of Pharmacy suspended a med spa drug license last month. Prescribers carry their own exposure, since the policy asks them to choose to prescribe a drug with little human data. Our earlier analysis of the risk for prescribers explains how that burden shifts to doctors.

For patients, the practical picture is unchanged for now. None of the six peptides is an FDA approved drug, a prescription is still required, and a pharmacy product made under the draft must meet testing and labeling rules that gray market vials sold as research chemicals do not. The AMA call for rescission adds political pressure but has no legal force on HHS. Pharmacy groups that spoke to Drug Topics expect the details to move before the policy is final. Anyone using or considering these peptides should treat the current conditions as provisional and talk to a licensed prescriber rather than rely on online claims about legal status.

Conclusion

The peptide policy comment period is over, but the policy itself is not settled. HHS has set no date for a revised text, the AMA wants it withdrawn, and state boards keep the final say on what a local pharmacy may fill. Until the FDA writes a rule, the six peptides remain unapproved drugs available only under a provisional enforcement stance.

Source Drug Topics, November 16, 2026; AMA press release, November 9, 2026; Polsinelli review of the HHS notice

Spotted an error? Tell us through the contact form; we follow the corrections policy.